Mono-Immunotherapy in Non-Small Cell Lung Cancer: Controversies and Challenges
Received Date : 05 Sep 2022
Accepted Date : 04 Oct 2022
Available Online : 01 Nov 2022
Doi: 10.37047/jos.2022-93252 - Article's Language: EN
J Oncol Sci. 2022;8(3):157-64
This is an open access article under the CC BY-NC-ND license
In recent years, we have seen a rapid transformation in the standard of care for non-small-cell lung cancer. Particularly in the last decade, immunotherapy has become common at almost every stage of lung cancer. Unfortunately, immunotherapies are not effective for every patient. There are many postulations about the ineffectiveness of immunotherapies, e.g., some non-targetable and/or co-occurring mutations might cause resistance to immunotherapy, while some actionable mutations might lead to a better response to immunotherapy. Hence, in addition to traditional predictive biomarkers, it is now recommended to investigate the presence of both targetable and non-targetable mutations by detailed genomic analysis to optimize the decision on mono-immunotherapy. There is ongoing research about the biomarkers that could be strong predictors of the outcomes with first-line and subsequent mono immunotherapy. In addition, the impact of clinical negative predictive biomarkers is debatable. The present work aims to discuss these controversies and challenges.
  1. Gandhi L, Rodríguez-Abreu D, Gadgeel S, et al. KEYNOTE-189 Investigators. Pembrolizumab plus Chemotherapy in Metastatic Non-Small-Cell Lung Cancer. N Engl J Med 2018; 378:2078-2092. [PubMed] 
  2. Paz-Ares L, Luft A, Vicente D, et al. KEYNOTE-407 Investigators. Pembrolizumab plus Chemotherapy for Squamous Non-Small-Cell Lung Cancer. N Engl J Med. 2018 22;379(21):2040-2051. [Crossref]  [PubMed] 
  3. Paz-Ares L, Ciuleanu TE, Cobo M, et al. First-line nivolumab plus ipilimumab combined with two cycles of chemotherapy in patients with non-small-cell lung cancer (CheckMate 9LA): an international, randomised, open-label, phase 3 trial. Lancet Oncol 2021; 22: 198-211. [Crossref]  [PubMed] 
  4. Socinski MA, Jotte RM, Cappuzzo F, et al. Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC. IMpower150 Study Group. N Engl J Med 2018;378:2288-301. [Crossref]  [PubMed] 
  5. Reck M, Rodríguez-Abreu D, Andrew G et al. KEYNOTE-024 Investigators. Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer. N Engl J Med 2016;375:1823-33. [Crossref]  [PubMed] 
  6. Herbst RS, Giaccone G, Marinis F, et al. Atezolizumab for First-Line Treatment of PD-L1-Selected Patients with NSCLC. N Engl J Med . 2020 1;383:1328-1339. [Crossref]  [PubMed] 
  7. Sezer A, Kilickap S, Gümüş M, et al. Cemiplimab monotherapy for first-line treatment of advanced non-small-cell lung cancer with PD-L1 of at least 50%: a multicentre, open-label, global, phase 3, randomised, controlled trial. Lancet. 2021; 13;397(10274):592-604. [Crossref]  [PubMed] 
  8. Mok TSK, Wu YL, Kudaba I, et al. Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial Lancet. 2019 4;393(10183):1819-1830.8. [PubMed] 
  9. Ricciuti B, Wang X, Alessi JV, et al. Association of High Tumor Mutation Burden in Non-Small Cell Lung Cancers With Increased Immune Infiltration and Improved Clinical Outcomes of PD-L1 Blockade Across PD-L1 Expression Levels. JAMA Oncol. 2022;8(8):1160-1168. [Crossref]  [PubMed]  [PMC] 
  10. Yang SR, Schultheis AM, Yu H, et al. Precision medicine in non-small cell lung cancer: Current applications and future directions. Semin Cancer Biol. 2022;84:184-198. [Crossref]  [PubMed] 
  11. Li BT, Ahn MJ, Goto K, et al. ,Open-label, randomized, multicenter, phase 3 study evaluating trastuzumab deruxtecan (T-DXd) as first-line treatment in patients with unresectable, locally advanced, or metastatic non-small cell lung cancer (NSCLC) harboring HER2 exon 19 or 20 mutations (DESTINY-Lung04). Journal of Clinical Oncology 40, no. 16_suppl (June 01, 2022) TPS9137-TPS9137. [Link] 
  12. Arbour KC, Khurana M, Dai T. Et al. Trial in progress: A phase 2 study of sotorasib as first-line treatment in patients with stage IV non-small cell lung cancer (NSCLC) whose tumors harbor a KRAS p.G12C mutation (CodeBreaK 201). Journal of Clinical Oncology 40, no. 16_suppl (June 01, 2022) TPS9150-TPS9150. [Link] 
  13. Paz-Ares L, Vicente D, Tafreshi A, et al. A Randomized, Placebo-Controlled Trial of Pembrolizumab Plus Chemotherapy in Patients. With Metastatic Squamous NSCLC: Protocol Specified Final Analysis of KEYNOTE-407. J Thorac Oncol. 2020;15(10):1657-1669. [Crossref]  [PubMed] 
  14. Rodríguez-Abreu D, Powell SF, Hochmair MJ, et al. Pemetrexed plus platinum with or without pembrolizumab in patients with previously untreated metastatic nonsquamous NSCLC: protocol-specified final analysis from KEYNOTE-189. Ann Oncol. 2021;32:881-895. [Crossref]  [PubMed] 
  15. Aguilar EJ, Ricciuti B, Gainor JF, et al. Outcomes to first-line pembrolizumab in patients with non-small-cell lung cancer and very high PD-L1 expression. Annals of Oncology 30: 1653-1659, 2019. [Crossref]  [PubMed] 
  16. Hellmann MD, Ciuleanu TE, Pluzanski A, et al. Nivolumab plus ipilimumab in lung cancer with a high tumor mutational burden. N Engl J Med. 2018; 378:2093-2104. [Crossref]  [PubMed]  [PMC] 
  17. Ready N, Hellmann MD, Awad MM, et al. First-line nivolumab plus ipilimumab in advanced non-small-cell lung cancer (CheckMate 568): outcomes by programmed death ligand 1 and tumor mutational burden as biomarkers.J Clin Oncol. 2019;37:992-1000. [Crossref]  [PubMed]  [PMC] 
  18. Carbone DP, Reck M, Paz-Ares L, et al; CheckMate 026 Investigators. First-line nivolumab in stage IV or recurrent non-small-cell lung cancer. N Engl J Med. 2017;376:2415-2426. [PubMed]  [PMC] 
  19. Singal G, Miller PG, Agarwala V, et al. Association of Patient Characteristics and Tumor Genomics With Clinical Outcomes Among Patients With Non-Small Cell Lung Cancer Using a Clinicogenomic Database, et al. JAMA. 2019;321:1391-1399. [Crossref]  [PubMed]  [PMC] 
  20. Gainor Jf, Shaw AT, Sequist LV, et al. EGFR mutations and ALk rearrangements are associated with low response rates to PD-1 pathway blockade in non-small cell lung cancer: a retrospective analysis. Clin Cancer Res. 2016;22(18):4585-4593. [Crossref]  [PubMed]  [PMC] 
  21. Lee Ck, Man J, Lord S, et al. Checkpoint inhibitors in metastatic EgfRmutated non-small cell lung cancer-a meta-analysis. J Thorac Oncol. 2017;12(2):403-407. [Crossref]  [PubMed] 
  22. Chen N, Fang W, Zhan J, et al. upregulation of PD-L1 by EgfR activation mediates the immune escape in EgfR-driven NSCLC: implication for optional immune targeted therapy for NSCLC patients with EgfR mutation. J Thorac Oncol. 2015;10(6):910-923. [Crossref]  [PubMed] 
  23. Dong ZY, Zhang JT, Liu SY, et al. EgfR mutation correlates with uninflamed phenotype and weak immunogenicity, causing impaired response to PD-1 blockade in non-small cell lung cancer. Oncoimmunology. 2017;6(11):e1356145. [Crossref]  [PubMed]  [PMC] 
  24. Wang S, Zhang Y, Wang Y, et al. Amphiregulin confers regulatory T cell suppressive function and tumor invasion via the EgfR/gSk-3β/foxp3 Axis. J Biol Chem. 2016;291(40):21085-21095. [Crossref]  [PubMed]  [PMC] 
  25. Mazieres J, Drilon A, Lusque A, et al. Immune checkpoint inhibitors for patients with advanced lung cancer and oncogenic driver alterations: results from the IMMUNOTARGET registry. Ann Oncol. 2019;30(8):1321- 1328. [Crossref]  [PubMed]  [PMC] 
  26. To KKW, Fong W, Cho WCS. Immunotherapy in treating EGFR-mutant lung cancer: current challenges and new strategies. front Oncol. May 2021;11:635007. [Crossref]  [PubMed]  [PMC] 
  27. Hastings K, Yu hA, Wei W, et al. EGFR mutation subtypes and response to immune checkpoint blockade treatment in non-small-cell lung cancer. Ann Oncol. 2019;30(8):1311-1320. [Crossref]  [PubMed]  [PMC] 
  28. Lau SCM, Fares AF, Le LW, et al. Subtypes of EGFR- and HER2-mutant metastatic NSCLC influence response to immune checkpoint inhibitors. Clin Lung Cancer. 2021;22(4):253-259. [Crossref]  [PubMed] 
  29. Guisier F, Dubos-Arvis C, Vi-as F, et al. Efficacy and safety of Anti-PD1 immunotherapy in patients with advanced NSCLC With BRAf, hER2, or MET mutations or RET translocation: GFPC 01-2018. J Thorac Oncol. 2020;15(4):628-636. [Crossref]  [PubMed] 
  30. Seegobin K, Majeed U, Wiest N, Manochakian R, Lou Y, Zhao Y. Immunotherapy in non-small cell lung cancer with actionable mutations other than EgfR. front Oncol. Dec 2021;11:750657. [Crossref]  [PubMed]  [PMC] 
  31. Kron A, Scheffler M, Heydt C, et al. genetic heterogeneity of MET-aberrant NSCLC and its impact on the outcome of immunotherapy. J Thorac Oncol. 2021;16(4):572-582. [Crossref]  [PubMed] 
  32. Spira AI, Wilson FH, Shapiro G, et al. Patient-reported outcomes (PRO) from the phase 2 CodeBreak 100 trial evaluating sotorasib in KRAS p.g12C mutated non-small cell lung cancer (NSCLC). Journal of Clinical Oncology. 2021;39(15_suppl):9057-9057. [Crossref] 
  33. Herbst RS, Lopes G, Kowalski DM, et al. Association of KRAS mutational status with response to pembrolizumab monotherapy given as firstline therapy for PD-L1-positive advanced nonsquamous NSCLC in kEYNOTE-042. Esmo. 2019;30(Supplement 11):xi63-xi64. [Crossref] 
  34. Ricciuti B, Arbour KC, Lin JJ, et al. Diminished efficacy of programmed death-(Ligand)1 inhibition in STk11- and kEAP1-mutant lung adenocarcinoma is affected by KRAS mutation status. J Thorac Oncol. 2022;17(3):399-410. [Crossref]  [PubMed] 
  35. Kus T, Aktas G. Letter to the editor concerning diminished efficacy of programmed death-(Ligand) 1 inhibition in STK11- and KEAP1-mutant lung adenocarcinoma ıs affected by KRAS mutation status. J Thorac Oncol. 2022;17(6):e63-e64. [Crossref]  [PubMed] 
  36. Hendriks LEL, Henon C, Auclin E, et al. Outcome of patients with nonsmall cell lung cancer and brain metastases treated with checkpoint inhibitors. J Thorac Oncol. 2019;14(7):1244-1254. [Crossref]  [PubMed] 
  37. Roviello G, Iannone LF, Bersanelli M, et al. The gut microbiome and efficacy of cancer immunotherapy. Pharmacol Ther. 2022;231:107973. [Crossref]  [PubMed] 
  38. Kroemer,G, Zitvogel, L. Cancer immunotherapy in 2017: The breakthrough of the microbiota. Nat Rev Immunol. 2018;30;18:87-88. [Crossref]  [PubMed] 
  39. Alexander JL, Wilson ID, Teare J, et al. Gut microbiota modulation of chemotherapy efficacy and toxicity. Nat Rev Gastroenterol Hepatol . 2017;14:356-365. [Crossref]  [PubMed] 
  40. Gopalakrishnan V, Spencer CN, Nezi L, et al. Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients. Science 2018 January 05;359 (6371):97-103. [PubMed]  [PMC] 
  41. Routy B, Chatelier EL, Derosa L, et al. Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors. Science. 2018; 5;359(6371):91-97. [PubMed] 
  42. Peng Z, Cheng S, Kou Y, et al. The Gut Microbiome Is Associated with Clinical Response to Anti-PD-1/PD-L1 Immunotherapy in Gastrointestinal Cancer. Cancer Immunol Res. 2020;8:1251-1261. [Crossref]  [PubMed] 
  43. He D, Li X, An R, et al. Response to PD-1-Based Immunotherapy for Non-Small Cell Lung Cancer Altered by Gut Microbiota Oncol Ther. 2021 9: 647-657. [Crossref]  [PubMed]  [PMC] 
  44. Chervin CS, Gajewski TF. Microbiome-based interventions: therapeutic strategies in cancer immunotherapy. Immunooncol Technol. 2020; 28;8:12-20. [Crossref]  [PubMed]  [PMC] 
  45. Kim H, Lee JE, Hong SH, et al. The effect of antibiotics on the clinical outcomes of patients with solid cancers undergoing immune checkpoint inhibitor treatment: a retrospective study. BMC Cancer. 2019; 19:1100. [Crossref]  [PubMed]  [PMC] 
  46. Zalcman G, Crespin A, Cervesi J, et al. Update of systematic reviews and meta-analyses studying the association between antibiotic use and clinical outcomes of cancer patients treated with immune checkpoint inhibitors. Annals of Oncology. 2020; 31 (suppl_7): S1428-S1440. [Crossref] 
  47. Cortellini A, Ricciuti B, Facchinetti F, et al. Antibiotic-exposed patients with non-small-cell lung cancer preserve efficacy outcomes following first-line chemo-immunotherapy. Ann Oncol. 2021;32:1391-1399. [Crossref]  [PubMed] 
  48. Spencer CN, McQuade JL, Gopalakrishnan V, et al. Dietary fiber and probiotics influence the gut microbiome and melanoma immunotherapy response. Observational Study Science. 2021; 24;374(6575):1632-1640. [PubMed]  [PMC]